-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although previous studies have shown that rituximab increases the risk of Pneumocystis jiroveci pneumonia (PJP), it is uncertain whether its primary prevention of PJP is reasonable
prevention
Recently, a research article was published in chest, an authoritative journal in the respiratory field, which aims to clarify whether the benefits of PJP primary prevention for patients treated with rituximab outweigh the potential risks of prevention?
This retrospective study included 3,524 patients who were treated with rituximab for the first time at tertiary referral centers in Korea from 2002 to 2018 (hematological diseases=2500; rheumatism=559; solid organ transplantation before/after=465 )
During the annual follow-up of 2759.
Infect
It can be seen that in patients receiving rituximab treatment, TMP-SMX prevention significantly reduces the incidence of PJP, and the safety is acceptable
In patients receiving rituximab treatment, TMP-SMX prevention significantly reduced the incidence of PJP, and the safety was fair
Original source:
Jun Won Park,et al.
Primary prophylaxis for Pneumocystis jiroveciipneumonia in patients receiving rituximab
in this message
